经膈隧道式Broviac导管:婴幼儿心脏手术围术期中心静脉通路的经济有效选择
该研究纳入220例1岁以下先天性心脏病手术患儿,比较使用与不使用隧道式Broviac导管的中心静脉通路策略的实际费用。经倾向性评分匹配后,隧道式Broviac导管组费用显著低于非隧道式组,且经皮中心静脉导管置入和放射干预次数更少。结论认为,心脏手术时常规放置隧道式Broviac导管比传统组合策略更经济有效。
要点
- 隧道式Broviac导管组经皮中心静脉导管置入4次,非隧道式组90次。
- 隧道式组放射干预6次,非隧道式组203次。
- 匹配后隧道式组费用中位数159.76美元,非隧道式组1277.26美元。
核心结论
- 心脏手术时常规放置隧道式Broviac导管,比传统胸腔内导管联合经皮中心静脉导管的策略费用更低。
- 费用效益通过减少经皮中心静脉导管置入次数及相关放射干预实现。
研究设计与样本
- 回顾性队列研究,纳入2014年1月至2016年12月连续220例1岁以下接受先天性心脏病手术的患儿。
- 按是否使用隧道式Broviac导管分为两组,进行倾向性评分匹配,采用Mann-Whitney U检验分析费用。
主要发现
- 隧道式组经皮中心静脉导管置入4次、放射干预6次;非隧道式组分别为90次和203次。
- 倾向性评分匹配后两组各82例,隧道式组费用总和17351.84美元、中位数159.76美元(四分位距128-159.76),非隧道式组总和72809.32美元、中位数1277.26美元(四分位距31.76-1277.26),P < .02。
临床怎么用
- 对于接受先天性心脏病手术的婴幼儿,可考虑在胸骨切开时放置经膈隧道式Broviac导管作为围术期中心静脉通路。
- 该策略可减少后续经皮中心静脉导管置入和放射干预的需求,从而降低费用。
局限性
- 研究为单中心回顾性设计,样本量有限,结论外推需谨慎。
- 原文未报告其他可能影响费用的混杂因素控制情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Infants undergoing congenital heart surgery require central venous lines which can be achieved by various combinations of transthoracic lines, percutaneous-indwelling central catheters and tunneled Broviac catheters. Transthoracic lines are removed by protocol prior to cardiac intensive care unit discharge (risk of bleeding), at which time percutaneous-indwelling central catheters are placed. Transdiaphragmatic tunneled Broviac catheters placed at the time of sternotomy, remain in place until hospital discharge, when they are safely removed at bedside. We characterized actual cost profiles associated with strategies that do versus do not include tunneled Broviac catheters. METHODS: From January 2014 to December 2016, we identified a study population of 220 consecutive patients under 1 year of age undergoing congenital heart surgery. Cost data were acquired from our electronic patient system interface database and office of finance. Our cohort was divided into 2 groups, tunneled Broviac catheter and nontunneled Broviac catheter. We calculated the total cost associated with each groups' central venous lines, propensity matched, and used the Mann-Whitney U test to analyze the results. RESULTS: Eighty-three (37.7%) of the 220 patients had tunneled Broviac catheters. The tunneled Broviac catheter group had 4 percutaneous-indwelling central catheter insertions and 6 radiological interventions while the nontunneled Broviac catheter group had 90 percutaneous-indwelling central catheters and 203 radiologic interventions. After propensity score matching, both groups were reduced to 82 patients and sum, median and interquartile range cost for tunneled Broviac catheters and nontunneled Broviac catheters was $17,351.84, $159.76 (128-159.76) versus $72,809.32, $1277.26 (31.76-1277.26), P < .02 respectively. CONCLUSIONS: Tunneled Broviac catheters, placed routinely at cardiac surgery, incur lower costs than the conventional combination of transthoracic lines and percutaneous-indwelling central catheters. The cost-effectiveness is achieved by reducing the number of percutaneous-indwelling central catheters and associated radiologic interventions.
引用
- Ghani MOA, Raees MA, Tang AR, et al. Transdiaphragmatic tunneled Broviac catheters: Cost-effective perioperative central venous access in infants undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2020. PMID: 32563580. doi:10.1016/j.jtcvs.2020.04.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。